Abbott Laboratories Corporation

Abbott Japan Co. Ltd.

Tokyo Institute of Technology

Abbott Japan LLC

The University of Tokyo

Toru Yoshimura

Makoto Komori

Barry Lee Dowell

Ken Komiya

Kenju Fujita

Eisaku Yoshida

Gangamani S Beligere

Ryotaro Chiba

Qiaoqiao Ruan

Michihiro Saito

Naohiko Koshikawa

Motoharu Seiki

John P Groff

Toshihiro Ogasawara

Barry L Dowell

Disclosed are methods for detecting a target nucleic acid in a sample. The methods include contacting the sample, in the presence of a polymerase and an endonuclease, with a first oligonucleotide comprising, in the 5' to 3&#x2032; direction, a first signal DNA generation sequence, an endonuclease recognition site, and a sequence complementary to the 3&#x2032; end of a target nucleic acid; a second oligonucleotide comprising, in the 5&#x2032; to 3&#x2032; direction, a second signal DNA generation sequence, an endonuclease recognition site, and a sequence that is homologous to the first signal DNA generation sequence of the first oligonucleotide; a third oligonucleotide comprising, in the 5&#x2032; to 3&#x2032; direction, a third signal DNA generation sequence, an endonuclease recognition site, and a sequence that is homologous to the second signal DNA generation sequence of the second oligonucleotide.

Sequence conversion and signal amplifier DNA cascade reactions and detection methods using same

Disclosed herein are biomarkers for hepatocellular carcinoma and pancreatic cancer. The biomarkers may be laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof. Also disclosed herein are methods of diagnosing, prognosing, classifying risk, and monitoring progression of hepatocellular carcinoma or pancreatic cancer by the detecting the level of laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof.

Methods of diagnosing hepatocellular carcinoma and pancreatic cancer

The present disclosure describes methods and kits for reducing interferences in immunoassays performed on solid phase and on samples containing serum or plasma, by adding an effective amount of a polycationic derivative of dextran to the assay.

Methods and kits for decreasing interferences from leukocytes in specific binding assays

Disclosed are methods for detecting a target nucleic acid in a sample. The methods include contacting said sample, in the presence of a polymerase and an endonuclease, with a sequence conversion oligonucleotide. Also disclosed are methods for detecting a target nucleic acid in a sample in which said sample is contacted, in the presence of a polymerase and an endonuclease, with a sequence conversion oligonucleotide and a signal amplifier oligonucleotide. The disclosure also provides compositions and kits comprising such sequence conversion and signal amplifier oligonucleotides.

Sequence conversion and signal amplifier DNA having poly DNA spacer sequences and detection methods using same

Disclosed are methods for detecting a target nucleic acid in a sample. The methods include contacting said sample, in the presence of a polymerase and an endonuclease, with a sequence conversion oligonucleotide having locked nucleic acids at select positions sufficient to decrease non-specific background signal amplification. Also disclosed are methods for detecting a target nucleic acid in a sample in which said sample is contacted, in the presence of a polymerase and an endonuclease, with a sequence conversion oligonucleotide and a signal amplifier oligonucleotide, both having locked nucleic acids at select positions sufficient to decrease non-specific background signal amplification. The disclosure also provides compositions and kits comprising such sequence conversion and signal amplifier oligonucleotides.

Sequence conversion and signal amplifier DNA having locked nucleic acids and detection methods using same

Methods and kits for reducing non-specific binding in an immunoassay for PIVKA-II in a test sample are described, in which the test sample is reacted with an anti-prothrombin antibody in the presence of one or more of the following additives: skim milk, saponin, CaCl, MgCl, and a sulfobetaine zwitterionic detergent.

Immunoassay methods and reagents for decreasing nonspecific binding

To provide a more convenient and more accurate method of assaying ProGRP by improving the stability of ProGRP which is known to be unstable in a biological sample. By using a blood sample in a condition in which a blood coagulation factor is not activated is used as a sample, the degradation of ProGRP is suppressed, whereby it is possible to store a sample for a long period of time and to improve the accuracy of an assay.

Immunoassay method for pro-gastrin-releasing peptide

Disclosed are methods for detecting a target nucleic acid in sample, which include contacting the sample with an oligonucleotide having a hairpin structure, where the oligonucleotide includes, in the 5' to 3&#x2032; direction, an arbitrary sequence, an endonuclease recognition site for a nicking reaction, a sequence complementary to the arbitrary sequence, and a sequence complementary to the target nucleic acid; a polymerase; and an endonuclease capable of nicking the endonuclease recognition site. The disclosure also provides compositions and kits comprising an oligonucleotide having a hairpin structure, where the oligonucleotide includes, in the 5&#x2032; to 3&#x2032; direction an arbitrary sequence, an endonuclease recognition site for a nicking reaction, a sequence complementary to the arbitrary sequence, and a sequence complementary to a target nucleic acid.

Covered sequence conversion DNA and detection methods

Methods for diagnosing rheumatoid arthritis (RA) are disclosed, using measurement of the CCL8 protein level in a test sample from a subject. Testing for CCL8 as an indicator of RA can be combined with testing for other indicators of RA, including clinical assessments, imaging or other RA markers such as Rheumatoid factor (RF). CCL8 testing can be used for discriminating RA from other diseases or conditions, evaluating the severity of RA. Related diagnostic reagents, kits, pharmaceutical compositions, and methods for identifying a candidate substance as a therapeutic agent for treating rheumatoid arthritis are also described.

Methods and reagents for diagnosing rheumatoid arthrtis

The present disclosure relates to antibodies and immunoassay methods for use in the diagnosis, treatment and prevention of hepatocellular carcinoma (HCC), liver cancer and related conditions.

Antibodies relating to PIVKA-II and uses thereof

The present invention relates to antibodies that may be used, for example, in the diagnosis, treatment and prevention of haepatocellular carcinoma (HCC), liver cancer and related conditions.

Antibodies relating to PIVKAII and uses thereof

A chromatography assay device and method for use with whole blood samples utilizing a red blood cell separating agent to aggregate red blood cells and permit plasma or serum to flow by capillary action and a neutralizing agent to neutralize any effects the red blood cell separating agent may have on the device and method.

Growing community of inventors

Matsudo, Japan

Toru Yoshimura